EpiAxis Therapeutics
EpiAxis Therapeutics is a Biotechnology company.
Backed by
Sydney AngelsEQUITY on December 18, 2020
About
EpiAxis Therapeutics is an Australian biotechnology company focused on developing therapeutic candidates and maintaining governance with biotech IP expertise on its board.
Mission
EpiAxis Therapeutics announced on Dec 18, 2020 that Rob McInnes was appointed as a non-executive director to its board. The appointment followed a successful fundraise supported by Sydney Angels. The company described the fundraise as successful but the article does not disclose the amount or the financing instrument. The article highlights McInnes as one of Australia’s leading biotech IP specialists. No additional operational, product, or financial metrics are provided in the article.
Quick Facts
Founded
2015
Funding
EQUITY
Industry
Biotechnology
Team Size
1-10
Headquarters
Canberra, Australian Capital Territory, Australia
Careers
View Careers Page
EpiAxis Therapeutics
https://jobs.ashbyhq.com/epiaxistherapeuticsNo open roles at this time.
Check their careers page for updates